RxDoctor Payments Data

Audrey Lacour, MD

Family Medicine · Houston, TXNPI 1437190774

Payments from drug & device makers

$1,284,044in general payments, 2019–2025

Across 1,016 payments — averaging $1263.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$360K
  • Eli Lilly$319K
  • Sanofi US Services Inc.$227K
  • Merck$169K
  • Pfizer$135K
  • AstraZeneca$44K
  • plus $30K from 20 others
$46,387in research payments, 2019–2025

Across 14 payments — averaging $3313.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Applied Therapeutics, Inc.$46K
  • Eli Lilly$143

What the payments were for

  • Food & beverage$1,328100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,284,044 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$78,328
Medicare patients
184
Services billed
798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$39,227
FarxigaDapagliflozin Propanediol15$20,136
JardianceEmpagliflozin14$19,529
JanuviaSitagliptin Phosphate19$18,139
MounjaroTirzepatide17$16,579
EliquisApixaban11$11,368
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$8,726
Levothyroxine Sodium119$1,647
Gabapentin76$1,509
SynthroidLevothyroxine Sodium17$1,336
Atorvastatin Calcium147$1,178
Losartan Potassium79$1,144
Ezetimibe32$971
Amlodipine Besylate150$935
Albuterol Sulfate HfaAlbuterol Sulfate33$807

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$353$39,22740 claims
AstraZenecaFarxiga$43,505$20,13615 claims
MerckJanuvia$169,317$18,13919 claims
Lilly USA, LLCMounjaro$214$16,57917 claims
PfizerEliquis$134,889$11,36811 claims
GSKTrelegy Ellipta$20$8,72612 claims
AbbVieSynthroid$20$1,33617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →